| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 01/22/2014 | EP2687523A1 Novel phenylpyridine derivative and drug containing same |
| 01/22/2014 | EP2687518A1 Nitrogen-containing saturated heterocyclic compound |
| 01/22/2014 | EP2687516A1 Inhibitors of C-FMS Kinase |
| 01/22/2014 | EP2687513A1 Drugs for inhibiting aggregation of proteins invoved in diseases linked to protein aggregation and/or neurodegenerative diseases |
| 01/22/2014 | EP2687512A1 Crystals of Laquinimod Sodium, and Process for the Manufacture Thereof |
| 01/22/2014 | EP2687511A1 Pyridinone derivatives as tissue transglutaminase inhibitors |
| 01/22/2014 | EP2687509A2 Dicarboxyimides derivatives for use in the treatment of cancer |
| 01/22/2014 | EP2687507A1 Nitrogen-containing condensed heterocyclic compound |
| 01/22/2014 | EP2687264A1 Macrophage Activating Factor for treatment of endometriosis |
| 01/22/2014 | EP2687222A1 Bleomycin hydrolase production promoting agent |
| 01/22/2014 | EP2687216A2 Pharmaceutical composition for treating aging-associated diseases, containing progerin expression inhibitor as active ingredient, and screening method of said progerin expression inhibitor |
| 01/22/2014 | EP2687215A1 Mesterolone pharmaceutical composition for androgens' deficiencies in woman |
| 01/22/2014 | EP2687213A1 Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
| 01/22/2014 | EP2687212A2 Medicament |
| 01/22/2014 | EP2687211A1 Use of phenethyl caffeate derivatives in the preparation of a medicament against tumor angiogenesis |
| 01/22/2014 | EP2687210A1 Stimulators and activators of soluble guanylate cyclase for use in the treatment of sickle cell anaemia and preservation of blood substitutes |
| 01/22/2014 | EP2687209A1 Nutritional support to prevent and/or mitigate bone marrow toxicity from a cancerous tumor |
| 01/22/2014 | EP2687208A1 Compositions and Methods for Treating Macular Degeneration |
| 01/22/2014 | EP2687207A1 System for delivering biologically active agents into an organism and method for producing said system |
| 01/22/2014 | EP2687206A1 Targeting of EWS-FLI1 as anti-tumor therapy |
| 01/22/2014 | EP2687205A2 Fentanyl transdermal patch |
| 01/22/2014 | EP2687204A1 Vector for pulmonary delivery, inducing agent, and uses |
| 01/22/2014 | EP2687103A1 Aqueous transparent oil-in-water emulsion comprising an emulsified carotenoid |
| 01/22/2014 | EP2686429A1 Compositions, process of preparation of said compositions and method of treating inflammatory diseases |
| 01/22/2014 | EP2686333A2 Isoxazolidine derivatives |
| 01/22/2014 | EP2686332A2 Isoxazolidine derivatives |
| 01/22/2014 | EP2686325A1 Morpholine-spirocyclic piperidine amides as modulators of ion channels |
| 01/22/2014 | EP2686324A1 Piperidine carboxamide spirohydantoin cgrp receptor antagonists |
| 01/22/2014 | EP2686321A1 Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases |
| 01/22/2014 | EP2686320A1 Tricyclic gyrase inhibitors |
| 01/22/2014 | EP2686319A1 Imidazo pyrazines |
| 01/22/2014 | EP2686318A1 Pyrrolopyridineamino derivatives as mps1 inhibitors |
| 01/22/2014 | EP2686317A2 Raf kinase inhibitors |
| 01/22/2014 | EP2686314A1 6,5-heterocyclic propargylic alcohol compounds and uses therefor |
| 01/22/2014 | EP2686313A1 Benz imidazole derivatives as inhibitors of glutaminyl cyclase |
| 01/22/2014 | EP2686312A1 N- cyclopropyl - n- piperidinylbenzamides as gpr119 modulators |
| 01/22/2014 | EP2686310A1 Benzodioxane inhibitors of leukotriene production |
| 01/22/2014 | EP2686308A2 Antimicrobial agents |
| 01/22/2014 | EP2686307A1 1,4-oxazepines as bace1 and/or bace2 inhibitors |
| 01/22/2014 | EP2686306A1 Benzo [b][1, 4]oxazin derivatives as calcium sensing receptor modulators |
| 01/22/2014 | EP2686302A1 Sulfonamide compounds having trpm8 antagonistic activity |
| 01/22/2014 | EP2686301A1 Montelukast intermediate camphorsulfonic salt |
| 01/22/2014 | EP2686300A1 New azaspirodecanone compounds |
| 01/22/2014 | EP2686299A1 Sec-hydroxycyclohexyl derivatives as hsl inhibitors for the treatment diabetes |
| 01/22/2014 | EP2686298A1 Substituted diphenyl derivatives |
| 01/22/2014 | EP2686295A1 Dihydronaphthalene and naphthalene derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators |
| 01/22/2014 | EP2686021A2 Oral formulations for promoting cellular purification |
| 01/22/2014 | EP2686017A1 An ophthalmic composition |
| 01/22/2014 | EP2686015A2 Overcoming resistance to erbb pathway inhibitors |
| 01/22/2014 | EP2686007A2 Methods of diagnosing and treating vascular associated maculopathy and symptoms thereof |
| 01/22/2014 | EP2685992A1 Amino-quinolines as kinase inhibitors |
| 01/22/2014 | EP2685991A1 Peritoneal dialysis solutions comprising glucose polymers |
| 01/22/2014 | EP2685990A1 Combination of anti-clusterin oligonucleotide with hsp90 inhibitor for the treatment of prostate cancer |
| 01/22/2014 | EP2685989A1 Combination of anti-clusterin oligonucleotide with androgen receptor antagonist for the treatment of prostate cancer |
| 01/22/2014 | EP2685988A2 Methods of treating breast cancer with anthracycline therapy |
| 01/22/2014 | EP2685987A2 Compositions and methods useful for ameliorating age related maladies |
| 01/22/2014 | EP2685986A2 Glucosylceramide synthase inhibitors |
| 01/22/2014 | EP2685985A1 Methods for treating leukemia and disorders mediated by cbf and runx1 proteins |
| 01/22/2014 | EP2685984A2 Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases |
| 01/22/2014 | EP2685983A1 Novel use of imidazotriazinones |
| 01/22/2014 | EP2685982A1 Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases |
| 01/22/2014 | EP2685981A1 Pyrrolopyridazine jak3 inhibitors and their use for the treatment of inflammatory and autoimmune diseases |
| 01/22/2014 | EP2685980A1 Methods and use of bifunctional enzyme-building clamp-shaped molecules |
| 01/22/2014 | EP2685979A1 Pharmaceutical compositions comprising sorbitan esters |
| 01/22/2014 | EP2685978A2 Cyclohexane substituted amino cyclopentane derivatives as useful ccr2 antagonists |
| 01/22/2014 | EP2685977A1 COMBINATIONS OF ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ACTIVATORS AND mGluR5 ANTAGONISTS FOR USE IN DOPAMINE INDUCED DYSKINESIA IN PARKINSON'S DISEASE |
| 01/22/2014 | EP2685976A1 Quinolone analogs for treating autoimmune diseases |
| 01/22/2014 | EP2685975A1 Novel use of benzofuranylsulfonates |
| 01/22/2014 | EP2685974A2 Inhibition and treatment of biofilms |
| 01/22/2014 | EP2685973A1 Compositions and methods for the treatment of musculoskeletal related diseases and disorders using metal ion-citrate analog complexes |
| 01/22/2014 | EP2685972A2 Inflammation and autoimmune disorder treatment using rar alpha selective agonists |
| 01/22/2014 | EP2685971A2 Compositions and methods for tissue engineering and cell based therapies |
| 01/22/2014 | EP2685970A1 Composition comprising a diindolylmethane and a retinoid to treat a skin condition |
| 01/22/2014 | EP2685968A1 Compositions and methods for the therapy and diagnosis of influenza |
| 01/22/2014 | EP2685967A1 Use of type a2 proanthocyanidins in gastroprotected form for the treatment of acute cystitis induced by fimbriated bacterial forms e |
| 01/22/2014 | EP2685966A1 Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor |
| 01/22/2014 | EP2685965A2 Combined formulation with improved stability |
| 01/22/2014 | EP2685963A2 Curcumin combination with anti-type 2 diabetic drugs for prevention and treatment of disease sequelae, drug-related adverse reactions, and improved glycemic control |
| 01/22/2014 | EP2685961A1 Method for treating neurotrauma |
| 01/22/2014 | EP2685960A1 Use of a sprayable composition comprising ambroxol |
| 01/22/2014 | EP2685828A1 Substituted 3-azabicyclo[3.1.0]hexane derivatives useful as ccr2 antagonists |
| 01/22/2014 | EP2685827A1 Pyrimidine cyclohexyl glucocorticoid receptor modulators |
| 01/22/2014 | EP2685826A1 Piperidinone carboxamide spirohydantoin cgrp receptor antagonists |
| 01/22/2014 | EP2685825A1 Substituted imadazopyrimidin-5(6h)-ones as allosteric modulators of mglur5 receptors |
| 01/22/2014 | EP2685824A1 Indole derivatives useful as ccr2 antagonists |
| 01/22/2014 | EP2685823A1 Treatment of cancer |
| 01/22/2014 | EP2685821A1 Nuclear hormone receptor modulators |
| 01/22/2014 | EP2488170B1 Compositions comprising tramadol and celecoxib in the treatment of pain |
| 01/22/2014 | EP2412744B1 Method for preparing branched functionalised polymers using branched polyol cores |
| 01/22/2014 | EP2037922B1 Prolyl hydroxylase inhibitors |
| 01/22/2014 | EP1407047B1 METHOD OF DETERMINING A CHEMOTHERAPEUTIC REGIMEN BASED ON GLUTATHIONE-S-TRANSFERASE Pi EXPRESSION |
| 01/22/2014 | CN103534593A The use anti-CXCL16 and anti- CXCR6 antibodies for the treatment or detecting cancer |
| 01/22/2014 | CN103534258A 酪氨酸激酶抑制剂 Tyrosine kinase inhibitors |
| 01/22/2014 | CN103534257A Pyrrolo [2, 3 -d] pyrimidine derivatives as inhibitors of tropomyosin- related kinases |
| 01/22/2014 | CN103534256A Macrocyclic hepatitis c serine protease inhibitors |
| 01/22/2014 | CN103534255A Substituted pyrazolopyrimidines as glucocerebrosidase activators |
| 01/22/2014 | CN103534254A Tri- and tetracyclic pyrazolo[3,4-b]pyridine compounds as antineoplastic agent |
| 01/22/2014 | CN103534250A Substituted indole derivatives for the treatment of immunological disorders |
| 01/22/2014 | CN103534249A Novel rock inhibitors |
| 01/22/2014 | CN103534248A Process for the preparation of anhydrous aripiprazole crystal form ii |